EDITORIAL TRACKER

RUO Supplier Documentation Tracker 2026

This tracker shows what each supplier publishes and what remains unverified. Placement reflects public documentation access at the review cutoff. It does not rate product quality, safety, or suitability, and it is not a purchasing guide.

Method: Companies are grouped by observable public documentation access. Report fields are recorded sample by sample. Official claims, public records, regulatory records, and community discussion remain separate evidence types.

Data cutoff: 2026-07-12

Disclosure: Sponsored placements do not affect this tracker's ordering, documentation findings, or editorial conclusions. A public report applies to the submitted sample and does not establish the condition of every batch or current inventory.

Eligibility

The canonical company record is published and its official site resolves.
The site states a research-use boundary.
At least one public COA, testing policy, or report page can be reviewed directly.
The review states what each checked document contains and what it does not contain.

Exclusions

Closed suppliers do not appear as active entries.
Companies without a verified official identity remain on hold.
A general testing claim or request-only policy is not public batch documentation.
Public instructions that conflict with an RUO boundary trigger a policy-review state.

At a glance

Current review states and largest gaps

Entry	Review state	Strongest documented fact	Largest gap	Checked
Valar Peptides	Extensive public batch documentation reviewed	Reviewed documents exposed batch or lot identifiers, analysis dates, HPLC results, measured quantity, endotoxin fields, instrument listings, and QC authorization.	Six of 36 checked catalog pages did not expose a working public report.	2026-07-12
Stemcode Peptides	Extensive public batch documentation reviewed	Public rows name Freedom Diagnostics and Janoshik Analytical.	The page states a 99 percent minimum while publishing results below 99 percent, including a tesamorelin record at 96.184 percent.	2026-07-12
Simple Peptide	Public batch documentation reviewed	Two reviewed Freedom Diagnostics reports include lot identifiers, HPLC and mass-spectrometry methods, identity, purity, and net content.	The table loads dynamically, so catalog coverage needs a repeatable crawl.	2026-07-12
Modern Aminos	Documentation access changed	The public quality page explains how batch numbers and QR codes are intended to connect a label to a report.	The catalog and all-COA archive were account-gated at the review cutoff.	2026-07-12
BioLongevity Labs	Public batch documentation reviewed	The public index exposes product and accession identifiers.	One normalized report does not establish catalog-wide coverage.	2026-07-12
Noxa Labs	Public batch library visible; normalization pending	Product names and multiple report images are publicly visible.	Every-batch, accredited-laboratory, and U.S.-synthesis statements remain company claims until individual reports and independent records are reviewed.	2026-07-12
Onyx Biolabs	Policy conflict under review	Public rows expose batch identifiers, HPLC purity, net content, and direct report links.	The FAQ states an RUO boundary but gives reconstitution volumes, syringe specifications, and dosing math.	2026-07-12

Shared review checks

Checks applied to every entry

Regulatory record: No action is linked in the canonical database. This is not a clearance statement.

Valar Peptides

Canonical company profile

Extensive public batch documentation reviewed

Thirty of 36 catalog pages checked through July 12 exposed working public report PDFs.

Observed

Reviewed documents exposed batch or lot identifiers, analysis dates, HPLC results, measured quantity, endotoxin fields, instrument listings, and QC authorization.
The site publishes a dedicated lab-report surface and an explicit RUO statement.

Limits and conflicts

Six of 36 checked catalog pages did not expose a working public report.
The terms do not name a legal entity or manufacturing address and select United Arab Emirates law while other pages claim U.S. manufacturing.
The terms reject reconstitution guidance while a public information page includes reconstitution instructions.
Manufacturing, GMP-comparable, ISO, and third-party verification statements remain company claims without facility or accreditation records.

Open questions

What legal entity operates the site?
Which facilities and laboratories support the manufacturing and verification claims?
Why did six checked catalog pages lack a working public report?

Community signal: Not used for placement. No substantive exact-name Reddit thread surfaced in the indexed search used for this review.

Last checked: 2026-07-12

Exact sources

Bottom line

Public document access is broad. Legal identity, manufacturing claims, and the policy conflict remain unresolved.

Stemcode Peptides

Canonical company profile

Extensive public batch documentation reviewed

The public results table exposes product, lot, reported result, report date, named laboratory, and report links.

Observed

Public rows name Freedom Diagnostics and Janoshik Analytical.
Direct PDFs identify the client, accession number, product lot, method, report date, and sample-specific limits.
One report is normalized in Peptide Report with identity, purity, net content, and endotoxin fields.

Limits and conflicts

The page states a 99 percent minimum while publishing results below 99 percent, including a tesamorelin record at 96.184 percent.
The claim that Freedom Diagnostics is ISO-certified needs an independent accreditation record.
Not every public row includes every test panel.

Open questions

How does the company reconcile sub-99 percent results with its stated minimum?
What current accreditation record supports the laboratory claim?

Community signal: Not used for placement. No attributable independent pattern was established.

Last checked: 2026-07-12

Exact sources

Bottom line

The public table supports report-level review. The stated purity threshold conflicts with published results.

Simple Peptide

Canonical company profile

Public batch documentation reviewed

A public lookup supports product, lot, and accession searches; two direct reports are normalized.

Observed

Two reviewed Freedom Diagnostics reports include lot identifiers, HPLC and mass-spectrometry methods, identity, purity, and net content.
One reviewed report also includes an endotoxin field.
The site publishes an explicit RUO boundary and business contact details.

Limits and conflicts

The table loads dynamically, so catalog coverage needs a repeatable crawl.
Two normalized reports do not establish full-catalog coverage.
Sterility and heavy-metal fields were not present on the two normalized reports.

Open questions

How many current catalog entries have a directly accessible report?
Which panels are run for each product category?

Community signal: Not used for placement. Search results were sparse and mixed with recommendation threads.

Last checked: 2026-07-12

Exact sources

Bottom line

The lookup and direct reports are reviewable. Catalog-wide coverage remains unmeasured.

Modern Aminos

Canonical company profile

Documentation access changed

The quality program describes batch and QR mapping, but the current catalog and COA archive require an account.

Observed

The public quality page explains how batch numbers and QR codes are intended to connect a label to a report.
One Freedom Diagnostics report is normalized with identity, purity, and endotoxin fields.

Limits and conflicts

The catalog and all-COA archive were account-gated at the review cutoff.
Claims about accreditation, sampling, quarantine, and rejected batches remain company statements until independently documented.
The site operates an affiliate program, so community mentions need attribution review.

Open questions

Can a reader without an account retrieve a batch-linked report?
Which current laboratory and accreditation records support the process claims?

Community signal: Not used for placement because promotional attribution cannot be ruled out.

Last checked: 2026-07-12

Exact sources

Bottom line

The public quality policy is visible, but current document access is account-gated and catalog coverage cannot be measured publicly.

BioLongevity Labs

Canonical company profile

Public batch documentation reviewed

A large filterable document index is public; one Freedom Diagnostics report is normalized.

Observed

The public index exposes product and accession identifiers.
The company publishes a separate RUO policy.
The normalized BPC-157 report contains identity, purity, and net-content fields.

Limits and conflicts

One normalized report does not establish catalog-wide coverage.
The site uses conflicting 80-plus and 150-plus catalog counts.
GMP-certified and cGMP-aligned language appears across different pages and requires facility-level confirmation.
Older and duplicate-looking entries need normalization before they are counted as current unique batches.

Open questions

What is the current catalog count and counting method?
Which facilities, laboratories, and credentials support the GMP and multi-lab claims?

Community signal: Not used for placement. Visible mentions include promotional and discount-code contexts.

Last checked: 2026-07-12

Exact sources

Bottom line

The archive supports deeper review. Conflicting catalog and manufacturing language needs resolution.

Noxa Labs

Canonical company profile

Public batch library visible; normalization pending

The certificate page names products and displays batch-specific report images; no Noxa report is normalized yet.

Observed

Product names and multiple report images are publicly visible.
The compliance page publishes an RUO and purchaser boundary.
A public address and contact details are present.

Limits and conflicts

Every-batch, accredited-laboratory, and U.S.-synthesis statements remain company claims until individual reports and independent records are reviewed.
Report images are not always stable direct report URLs.
No report is normalized in Peptide Report, so method and field coverage cannot yet be summarized.

Open questions

Which reports name the originating laboratory and include stable batch identifiers?
Do the consumer-oriented product presentation and RUO policy remain consistent across the site?

Community signal: Not used for placement. No attributable independent pattern was established.

Last checked: 2026-07-12

Exact sources

Bottom line

A public certificate surface exists. Report-level normalization and independent verification remain pending.

Onyx Biolabs

Canonical company profile

Policy conflict under review

The public database exposes batch rows and direct reports, including a July 2026 Kovera report with several analytical fields.

Observed

Public rows expose batch identifiers, HPLC purity, net content, and direct report links.
A reviewed Kovera report also contains LC-MS identity, endotoxin, heavy-metal, conformity, and chromatogram fields.
The archive also contains legacy reports from Freedom Diagnostics and Forever Young Pharmacy.

Limits and conflicts

The FAQ states an RUO boundary but gives reconstitution volumes, syringe specifications, and dosing math.
The public documentation appears beside discount-code and affiliate promotion.
Every-batch and maximum-purity language must not replace sample-level findings.
The current Kovera-only narrative does not explain older reports from other issuers.

Open questions

How does the company reconcile instructional FAQ content with its RUO statement?
What roles did the named legacy report issuers and current Kovera laboratory play?

Community signal: Not used for placement. Affiliate and discount structures raise attribution concerns.

Last checked: 2026-07-12

Exact sources

Bottom line

The report database is detailed. The RUO policy conflict and report-issuer history need direct resolution.